LSE:HLMA.L 19 January 2026 - 9 February 2026

June 14, 2026, 12:02 AM EDT. Christian Heidbreder, Chief Scientific Officer at Indivior Pharmaceuticals, sold 18,586 shares valued at $707,383 on June 11, 2026, representing 7.54% of his holdings. Post-sale, he retains 227,923 shares worth about $8.69 million, maintaining a 0.18% stake. The sale occurred during a significant stock price surge, with Indivior shares rising 177% over the past year, reflecting strong market performance amid growth in opioid dependence therapies. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, not signaling insider concerns. Indivior's strategy focuses on buprenorphine-based addiction treatments, with $1.29 billion in trailing twelve-month revenue and $252 million net income, underscoring its established market position and ongoing research-led expansion.